Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat.
The head twitch response in mice produced by injection of 5-hydroxytryptophan (100 mg/kg i.p.) and carbidopa (25 mg/kg i.p.) was enhanced by administration of clenbuterol (0.5 mg/kg i.p.), a beta-adrenoceptor agonist. Clenbuterol also enhanced the hyperactivity syndrome in rats produced by quipazine...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1983
|
| _version_ | 1797083875525001216 |
|---|---|
| author | Nimgaonkar, V Green, A Cowen, P Heal, D Grahame-Smith, D Deakin, J |
| author_facet | Nimgaonkar, V Green, A Cowen, P Heal, D Grahame-Smith, D Deakin, J |
| author_sort | Nimgaonkar, V |
| collection | OXFORD |
| description | The head twitch response in mice produced by injection of 5-hydroxytryptophan (100 mg/kg i.p.) and carbidopa (25 mg/kg i.p.) was enhanced by administration of clenbuterol (0.5 mg/kg i.p.), a beta-adrenoceptor agonist. Clenbuterol also enhanced the hyperactivity syndrome in rats produced by quipazine (25 mg/kg i.p.), a 5-hydroxytryptamine (5-HT) agonist. This enhancement was not prevented by depletion of 5-HT in brain with p-chlorophenylalanine or after pretreatment with prazosin. The behavioural responses of the rats to administration of the alpha 2-adrenoceptor agonist, clonidine, was unaltered by acute or longer-term administration of clenbuterol. Following chronic administration of clenbuterol (5 mg/kg daily for 14 days), a procedure resulting in down-regulation of central beta-adrenoceptors, a larger dose of clenbuterol was necessary to enhance the quipazine-induced hyperactivity, suggesting that the mechanism of enhancement involved central post-synaptic beta-adrenoceptors. Further evidence for this conclusion was that a lesion of central noradrenaline pathways produced by 6-hydroxydopamine did not abolish the clenbuterol-induced enhancement of the quipazine-mediated behaviour. The binding characteristics of 5-HT2-receptors were unchanged by acute or chronic administration of clenbuterol. Clenbuterol (5 mg/kg) increased the percentage of plasma free (non-albumin bound) tryptophan, plasma free fatty acid concentration and the concentration of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in the brain. The increase in 5-HT turnover in brain was prevented by pretreatment with the beta 1-adrenoceptor antagonist atenolol, which enters the brain poorly. It is therefore suggested that the clenbuterol-induced increase in 5-HT metabolism results from the increase in the concentration of plasma free fatty acid which increases plasma free tryptophan and thus increases the concentration of tryptophan in brain and 5-HT synthesis in brain. The clenbuterol-induced enhancement of 5-HT-mediated behaviour is therefore not associated with its effect on 5-HT metabolism. The data are discussed in relation to that obtained after administration of antidepressant drugs. |
| first_indexed | 2024-03-07T01:47:41Z |
| format | Journal article |
| id | oxford-uuid:98faf93b-aee9-4567-9889-45a83c79b0b2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:47:41Z |
| publishDate | 1983 |
| record_format | dspace |
| spelling | oxford-uuid:98faf93b-aee9-4567-9889-45a83c79b0b22022-03-27T00:10:57ZStudies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:98faf93b-aee9-4567-9889-45a83c79b0b2EnglishSymplectic Elements at Oxford1983Nimgaonkar, VGreen, ACowen, PHeal, DGrahame-Smith, DDeakin, JThe head twitch response in mice produced by injection of 5-hydroxytryptophan (100 mg/kg i.p.) and carbidopa (25 mg/kg i.p.) was enhanced by administration of clenbuterol (0.5 mg/kg i.p.), a beta-adrenoceptor agonist. Clenbuterol also enhanced the hyperactivity syndrome in rats produced by quipazine (25 mg/kg i.p.), a 5-hydroxytryptamine (5-HT) agonist. This enhancement was not prevented by depletion of 5-HT in brain with p-chlorophenylalanine or after pretreatment with prazosin. The behavioural responses of the rats to administration of the alpha 2-adrenoceptor agonist, clonidine, was unaltered by acute or longer-term administration of clenbuterol. Following chronic administration of clenbuterol (5 mg/kg daily for 14 days), a procedure resulting in down-regulation of central beta-adrenoceptors, a larger dose of clenbuterol was necessary to enhance the quipazine-induced hyperactivity, suggesting that the mechanism of enhancement involved central post-synaptic beta-adrenoceptors. Further evidence for this conclusion was that a lesion of central noradrenaline pathways produced by 6-hydroxydopamine did not abolish the clenbuterol-induced enhancement of the quipazine-mediated behaviour. The binding characteristics of 5-HT2-receptors were unchanged by acute or chronic administration of clenbuterol. Clenbuterol (5 mg/kg) increased the percentage of plasma free (non-albumin bound) tryptophan, plasma free fatty acid concentration and the concentration of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in the brain. The increase in 5-HT turnover in brain was prevented by pretreatment with the beta 1-adrenoceptor antagonist atenolol, which enters the brain poorly. It is therefore suggested that the clenbuterol-induced increase in 5-HT metabolism results from the increase in the concentration of plasma free fatty acid which increases plasma free tryptophan and thus increases the concentration of tryptophan in brain and 5-HT synthesis in brain. The clenbuterol-induced enhancement of 5-HT-mediated behaviour is therefore not associated with its effect on 5-HT metabolism. The data are discussed in relation to that obtained after administration of antidepressant drugs. |
| spellingShingle | Nimgaonkar, V Green, A Cowen, P Heal, D Grahame-Smith, D Deakin, J Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title | Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title_full | Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title_fullStr | Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title_full_unstemmed | Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title_short | Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. |
| title_sort | studies on the mechanisms by which clenbuterol a beta adrenoceptor agonist enhances 5 ht mediated behaviour and increases metabolism of 5 ht in the brain of the rat |
| work_keys_str_mv | AT nimgaonkarv studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat AT greena studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat AT cowenp studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat AT heald studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat AT grahamesmithd studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat AT deakinj studiesonthemechanismsbywhichclenbuterolabetaadrenoceptoragonistenhances5htmediatedbehaviourandincreasesmetabolismof5htinthebrainoftherat |